Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Q2 Results 2026 (FY27): Revenue ₹192.3 Cr, PAT ₹36.6 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #4 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Senores Pharmaceuticals Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 revenue from operations: ₹192.3 Cr, up 24.9% YoY from ₹153.9 Cr in Q2 FY26 (Page 10). EBITDA (Q2 FY27): ₹57.7 Cr, up 38.3% YoY from ₹41.7 Cr in Q2 FY26 - EBITDA Margin (Q2 FY27): 30.0%, up 290 bps YoY from 27.1% in Q2 FY26 - Profit After Tax (PAT) (Q2 FY27): ₹36.6 Cr, up
From Senores Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 29 Oct 2026.
Revenue & Sales Performance
- Q2 FY27 revenue from operations: ₹192.3 Cr, up 24.9% YoY from ₹153.9 Cr in Q2 FY26 (Page 10).
- Segment revenue growth YoY in Q2 FY27:
- Regulated Markets: ₹136.7 Cr, +27.9%
- Emerging Markets: ₹38.4 Cr, +21.2%
- Branded Generics: ₹9.5 Cr, -20.5% (Page 9).
- 60+ branded generic products launched; 64 approved ANDAs, 23 commercialized with 54 strengths, and 41 molecules with 130 strengths in the pipeline (Pages 3, 6, 21).
- Outlook: H2 expected to be considerably better than H1 due to anticipated launches and a robust approved & pipeline product base (Page 5).
2 more points from Senores Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Senores Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Investment of ₹41.98 Cr planned for setting up sterile injection manufacturing at Atlanta Facility; ₹6.98 Cr utilized till Sep 2026, ₹35 Cr unutilized.
- Expansion capital expenditure of ₹25 Cr for Apnar manufacturing facility in Vadodara; ₹1.69 Cr utilized, ₹23.32 Cr unutilized as of Sep 2026.
- Capital expenditure of ₹24.63 Cr for expanding OSD manufacturing in Atlanta; ₹7.14 Cr utilized, ₹17.48 Cr unutilized as of Sep 2026.
- Senores API Plant II with 144 MT annual installed capacity is USFDA approvable.
- Apnar Pharma Plant has annual installed capacity of 275 Mn units, expandable to 600 Mn units.
2 more points from Senores Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Senores Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Senores Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Senores Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹192 Cr, net profit ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Senores Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Senores Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Senores Pharmaceuticals Ltd Q2 FY27 results?
Q2 FY27 revenue from operations: ₹192.3 Cr, up 24.9% YoY from ₹153.9 Cr in Q2 FY26 (Page 10). EBITDA (Q2 FY27): ₹57.7 Cr, up 38.3% YoY from ₹41.7 Cr in Q2 FY26 - EBITDA Margin (Q2 FY27): 30.0%, up 290 bps YoY from 27.1% in Q2 FY26 - Profit After Tax (PAT) (Q2 FY27): ₹36.6 Cr, up
What is Senores Pharmaceuticals Ltd share price analysis?
Senores Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 48.3 with a market cap of ₹6,101 Cr. Investors should review the full earnings analysis for detailed insights.
Is Senores Pharmaceuticals Ltd planning capital expenditure?
Investment of ₹41.98 Cr planned for setting up sterile injection manufacturing at Atlanta Facility; ₹6.98 Cr utilized till Sep 2026, ₹35 Cr unutilized.
Keep Senores Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.